EN

DRAFT

COMMISSION REGULATION (EU) …/…

of XXX

amending Annex II to Regulation (EC) 1107/2009 by setting out scientific criteria for the determination of endocrine disrupting properties

(Text with EEA relevance)
COMMISSION REGULATION (EU) .../…

of XXX

amending Annex II to Regulation (EC) 1107/2009 by setting out scientific criteria for the
determination of endocrine disrupting properties

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1107/2009 of the European Parliament and of the
Council of 21 October 2009 concerning the placing of plant protection products on the market
and repealing Council Directives 79/117/EEC and 91/414/EEC1, and in particular
Article 78(1)(a) and the second paragraph of point 3.6.5. of Annex II thereof,

Whereas:

(1) Scientific criteria for the determination of endocrine disrupting properties of active
substances, safeners and synergists, should be developed taking into account the
objectives of Regulation (EC) No 1107/2009, which are to ensure a high level of
protection of both human and animal health and the environment, in particular
ensuring that substances or products placed on the market have no harmful effect on
human or animal health or unacceptable effects on the environment, and to improve
the functioning of the internal market while improving agricultural production.

(2) In 2002, the World Health Organisation (WHO) through its International Programme
for Chemical Safety proposed a definition for endocrine disruptors2 and in 2009 a
definition of adverse effects3. Those definitions have by now reached the widest
consensus among scientists. The European Food Safety Authority (‘the Authority’)
endorsed those definitions in its Scientific Opinion on endocrine disruptors adopted on
28 February 20134 (hereinafter "the Scientific Opinion of the Authority"). It is also the
view of the Scientific Committee on Consumer Safety5. It is therefore appropriate to
base the criteria for the determination of endocrine disrupting properties on those
WHO definitions.

Assessment of the State-of-the-science of Endocrine Disruptors. WHO/PCS/EDC/02.2, publicly
4 “Scientific Opinion on the hazard assessment of endocrine disruptors: Scientific criteria for
identification of endocrine disruptors and appropriateness of existing test methods for assessing effects
mediated by these substances on human health and the environment”, EFSA Journal 2013;11(3):3132,
(SCCS/1544/14).
In order to implement those criteria, weight of evidence should be applied considering in particular the approach provided for in Regulation (EC) No 1272/2008 of the European Parliament and of the Council\(^6\) on the weight of evidence. Previous experience with the Guidance document on standardised test guidelines for evaluating chemicals for endocrine disruption of OECD\(^7\) should also be considered. In addition, the implementation of the criteria should be based on all relevant scientific evidence, including studies submitted in accordance with the current regulatory data requirements of Regulation (EC) No 1107/2009. These studies are mostly based on internationally agreed study protocols.

As the specific scientific criteria laid down by this Regulation reflect the current scientific and technical knowledge and are to be applied instead of the criteria currently set out in point 3.6.5. of Annex II to Regulation (EC) No 1107/2009, they should be provided for in that Annex.

In order to take into account the current scientific and technical knowledge, specific scientific criteria should also be specified in order to identify active substances, safeners or synergists having endocrine disrupting properties that may cause adverse effects on non-target organisms. Therefore point 3.8.2. of Annex II to Regulation (EC) No 1107/2009 should be amended to introduce these specific criteria.

The criteria for the determination of endocrine disrupting properties reflect the current state of scientific and technical knowledge and allow identifying active substances having endocrine disrupting properties more accurately. The new criteria should therefore apply as soon as possible, except where the relevant Committee has voted on the draft Regulation presented to it without that Regulation having been adopted by the Commission by [Date of EIF]. The Commission will consider the implications for each procedure pending under Regulation (EC) No 1107/2009 and, where necessary, take appropriate measures with due respect for the rights of the applicants. This may include a request for additional information from the applicant and/or for additional scientific input from the Rapporteur Member State and the Authority.

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,

HAS ADOPTED THIS REGULATION:

**Article 1**

Annex II to Regulation (EC) No 1107/2009 is amended in accordance with the Annex to this Regulation.

**Article 2**

Point 3.6.5 and point 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by this Regulation, shall apply as of [date of EIF of the Regulation], except for procedures where the Committee has voted on the draft Regulation presented to it without that draft Regulation having been adopted by [date of EIF of the Regulation].

---


\(^7\) OECD Series on Testing and Assessment No. 150.
Article 3

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels,

For the Commission
The President
Jean-Claude JUNCKER
Brussels, XXX
SANTE-2016-12020-REV 1
C(2016) 3751 projet

ANNEX 1

DRAFT

ANNEX

to the

COMMISSION REGULATION (EU) .../...

amending Annex II to Regulation (EC) 1107/2009 by setting out scientific criteria for the
determination of endocrine disrupting properties
Annex II to Regulation (EC) No 1107/2009 is amended as follows:

(1) In Point 3.6.5, the following paragraphs are added after the fourth paragraph:

"From [date of EIF], an active substance, safener or synergist shall be considered as having endocrine disrupting properties that may cause adverse effect in humans if, based on points (1) to (5) of the sixth paragraph it is a substance that meets all of the following criteria, unless there is information demonstrating that the adverse effects identified are not relevant to humans:

(1) it shows an adverse effect in an intact organism or its progeny, which is a change in the morphology, physiology, growth, development, reproduction or life span of an organism, system or (sub)population that results in an impairment of functional capacity, an impairment of the capacity to compensate for additional stress or an increase in susceptibility to other influences;

(2) it has an endocrine mode of action, i.e. it alters the function(s) of the endocrine system;

(3) the adverse effect is a consequence of the endocrine mode of action.

The identification of an active substance, safener or synergist as having endocrine disrupting properties that may cause adverse effect in humans in accordance with the fifth paragraph shall be based on all of the following:

(1) all available relevant scientific data:

(a) scientific data generated in accordance with internationally agreed study protocols (in vivo studies or adequately validated alternative test systems predictive of adverse effects in humans or animals; as well as in vivo, in vitro, or, if applicable, in silico studies informing about endocrine modes of action). In particular, those internationally agreed study protocols listed in the Commission Communications in the framework of setting out the data requirements for active substances and plant protection products, in accordance with this Regulation shall be considered;

(b) other scientific data selected applying a systematic review methodology, in particular following guidance on literature data which is listed in the Commission Communications in the framework of setting out the data requirements for active substances and plant protection products, in accordance with this Regulation;

(2) an assessment of the available relevant scientific data based on a weight of evidence approach in order to establish whether the criteria set out in the fifth paragraph are fulfilled;

(3) in applying the weight of evidence determination, the assessment of the scientific evidence shall, in particular, consider all of the following factors:

(a) both positive and negative results;

(b) the relevance of the study designs, for the assessment of adverse effects and of the endocrine mode of action;
(c) the biological plausibility of the link between the adverse effects and the endocrine mode of action;

(d) the quality and consistency of the data, considering the pattern and coherence of the results within and between studies of a similar design and across different species;

(e) the route of exposure, toxicokinetic and metabolism studies;

(f) the concept of the limit dose, and international guidelines on maximum recommended doses and for assessing confounding effects of excessive toxicity;

(4) adverse effects that are non-specific secondary consequences of other toxic effects shall not be considered for the identification of the substance as endocrine disruptor;

(5) where there is information demonstrating that the adverse effects are clearly not relevant for humans the substance shall not be considered a human endocrine disruptor.”

(2) In Point 3.8.2. the following paragraphs are added after the sole paragraph:

From [date of EIF], an active substance, safener or synergist shall be considered as having endocrine disrupting properties that may cause adverse effects on non-target organisms if, based on points (1) to (5) of the third paragraph, it is a substance that meets all of the following criteria, unless there is information demonstrating that the adverse effects identified are not relevant at the (sub)population level for non-target organisms:

(1) it shows an adverse effect in non-target organisms, which is a change in the morphology, physiology, growth, development, reproduction or life span of an organism, system or (sub)population that results in an impairment of functional capacity, an impairment of the capacity to compensate for additional stress or an increase in susceptibility to other influences;

(2) it has an endocrine mode of action, i.e. it alters the function(s) of the endocrine system;

(3) the adverse effect is a consequence of the endocrine mode of action.

The identification of an active substance, safener or synergist as having endocrine disrupting properties that may cause adverse effects on non-target organisms in accordance with the second paragraph shall be based on all of the following:

(1) all available relevant scientific data:

(a) scientific data generated in accordance with internationally agreed study protocols (in vivo studies or adequately validated alternative test systems predictive of adverse effects in humans or animals; as well as in vitro, in silico studies informing about endocrine modes of action). In particular, those internationally agreed study protocols listed in the Commission Communications in the framework of setting out the data requirements for active substances and plant protection products, in accordance with this Regulation shall be considered;
(b) other scientific data selected applying a systematic review methodology, in particular following guidance listed in the Commission Communications in the framework of setting out the data requirements for active substances and plant protection products, in accordance with this Regulation;

(2) an assessment of the available relevant scientific data based on a weight of evidence approach in order to establish whether the criteria set out in the second paragraph are fulfilled;

(3) in applying the weight of evidence determination, the assessment of the scientific evidence shall consider all of the following factors:

(a) both positive and negative results, discriminating between taxonomic groups (e.g. mammals, birds, fish) where relevant;

(b) the relevance of the study design for the assessment of the adverse effects and its relevance at the (sub)population level, and for the assessment of the endocrine mode of action;

(c) the adverse effects on reproduction, growth/development, and other relevant adverse effects which are likely to impact on (sub)populations. Adequate, reliable and representative field or monitoring data and/or results from population models shall as well be considered where available;

(d) the biological plausibility of the link between the adverse effects and the endocrine mode of action;

(e) the quality and consistency of the data, considering the pattern and coherence of the results within and between studies of a similar design and across different taxonomic groups;

(f) the concept of the limit dose and international guidelines on maximum recommended doses and for assessing confounding effects of excessive toxicity.

(4) Adverse effects that are non-specific secondary consequences of other toxic effects shall not be considered for the identification of the substance as endocrine disruptor with respect to non-target organisms;

(5) If the mode of action of the active substance being assessed, as defined under point 3.6. of Part A of the Annex to Commission Regulation (EU) No 283/2013*, consists of regulating moulting and/or growth of harmful organisms via their endocrine system, it shall not be considered for the identification of the substance as endocrine disruptor with respect to non-target organisms."

________________